Author/Editor		Šebeštjen, Miran
Title		Vpliv statinov in fibratov na funkcionalne in morfološke lastnosti arterijske stene pri bolnikih s kombinirano hiperlipidemijo
Type		monografija
Place		Ljubljana
Publisher		Univerza v Ljubljani, Medicinska fakulteta
Publication year		2000
Volume		str. 61
Language		slo
Abstract		Background: Endothelial dysfunction manifested by diminished flow-mediated dilation (FMD) of brachial artery has been shown to improve after treatment with several lipolytics in patients with hypercholesterolemia. However, there is no data of the effects of cerivastatin, new HMG-CoA reductase inhibitor and fibric acid derivate fenofibrate on the endothelial dysfunction in subjects with combined hyperlipidemia. Subjects and methods: Forty middle-aged males with combined hyperlipidemia with no other atherogenic risk factors were randomised, after 6 week run-in phase with AHA step I diet treatment, to 12 week treatment either with fenofibrate (250 mg daily) or cerivastatin. Cerivastatin was given in daily dose of 0,2 mg for 6 weeks and was increased to 0,4 mg daily in 10 patients, who did not achieve LDL-cholesterol goal of <3,0 mmol/I. At the beginning and every 6 weeks physical examination and anthropometric measurement were performed and blood total, LDL and HDL cholesterol, glucose, insulin, apolipoprotein A1, apolipoprotein B, lipoprotein (a), tissue type plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor (PAI-1) antigen and activity, fibrinogen and euglobulin clot lysis time were detennined. We estimated the presence of small, dense LDL particles with relation LDL cholesterol/apolipoprotein B. Insulin resistance was calculated by using HOMA mathematical model. The endothelium-dependent and endothelium-independent dilation were calculated using the diameters of the brachial artery measured by high resolution ultrasound at rest, after reactive hyperemia and after sublingual glyceriltrinitrate. (Abstracts truncated at 2000 characters.)
Descriptors		HYPERLIPIDEMIA PROCETOFEN BRACHIAL ARTERY ENDOTHELIUM, VASCULAR LIPOPROTEINS, LDL CHOLESTEROL CHOLESTEROL LIPOPROTEINS, HDL CHOLESTEROL TRIGLYCERIDES BLOOD GLUCOSE INSULIN APOLIPOPROTEINS A APOLIPOPROTEINS B LIPOPROTEIN(A) FIBRINOGEN ALTEPLASE INSULIN RESISTANCE PLASMINOGEN ACTIVATOR INHIBITOR 1 HMG-COA REDUCTASE INHIBITORS NITROGLYCERIN